BenMohamed and colleagues showed reduced tumor burden and increased survival in response to self-adjuvanting vaccines containing four copies of the TN antigen in concert with a CD8 epitope from the breast cancer antigen human epidermal growth factor receptor 2 (Her2) and the pan HLA DR-binding Epitope or “PADRE” (Renaudet et al., 2010). The gene discussed is CD8A; the disease is breast cancer.